StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.67+0.03 (+4.01%)

Close on Nov 16, 2026Market cap $40.39MP/E –Yield –

Aldeyra Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Aldeyra Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.63M, down 63.7% year over year. For fiscal 2025 it was $25.66M, down 46.8% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $48.22M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.66M-46.8%
FY2024Dec 31, 2024$48.22M+63.7%
FY2023Dec 31, 2023$29.46M-37.7%
FY2022Dec 31, 2022$47.31M+5.3%
FY2021Dec 31, 2021$44.94M+82.1%
FY2020Dec 31, 2020$24.68M-44.4%
FY2019Dec 31, 2019$44.35M+48.7%
FY2018Dec 31, 2018$29.82M+82.9%
FY2017Dec 31, 2017$16.30M+23.7%
FY2016Dec 31, 2016$13.18M+74.0%
FY2015Dec 31, 2015$7.57M+104.3%
FY2014Dec 31, 2014$3.71M+140.5%
FY2013Dec 31, 2013$1.54M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.48M-59.0%
Q1 FY2026Mar 31, 2026$2.41M-67.5%
Q4 FY2025Dec 31, 2025$4.30M-70.6%
Q3 FY2025Sep 30, 2025$5.43M-56.3%
Q2 FY2025Jun 30, 2025$8.51M-43.2%
Q1 FY2025Mar 31, 2025$7.42M+20.1%
Q4 FY2024Dec 31, 2024$14.63M+240.4%
Q3 FY2024Sep 30, 2024$12.44M+78.7%
Q2 FY2024Jun 30, 2024$14.97M+115.0%
Q1 FY2024Mar 31, 2024$6.18M-45.0%
Q4 FY2023Dec 31, 2023$4.30M-52.0%
Q3 FY2023Sep 30, 2023$6.96M-39.7%
Q2 FY2023Jun 30, 2023$6.96M-52.2%
Q1 FY2023Mar 31, 2023$11.24M-8.2%
Q4 FY2022Dec 31, 2022$8.96M-30.2%
Q3 FY2022Sep 30, 2022$11.54M-10.5%
Q2 FY2022Jun 30, 2022$14.57M+27.0%
Q1 FY2022Mar 31, 2022$12.23M+58.3%
Q4 FY2021Dec 31, 2021$12.84M+82.7%
Q3 FY2021Sep 30, 2021$12.89M+110.2%
Q2 FY2021Jun 30, 2021$11.47M+134.8%
Q1 FY2021Mar 31, 2021$7.73M+16.5%
Q4 FY2020Dec 31, 2020$7.03M-26.9%
Q3 FY2020Sep 30, 2020$6.13M-62.2%
Q2 FY2020Jun 30, 2020$4.89M-54.2%
Q1 FY2020Mar 31, 2020$6.63M-15.5%
Q4 FY2019Dec 31, 2019$9.61M+12.5%
Q3 FY2019Sep 30, 2019$16.22M+105.9%
Q2 FY2019Jun 30, 2019$10.66M+92.3%
Q1 FY2019Mar 31, 2019$7.85M+121.8%
Q4 FY2018Dec 31, 2018$8.55M+122.1%
Q3 FY2018Sep 30, 2018$7.88M+133.9%
Q4 FY2017Dec 31, 2017$5.55M+60.9%
Q3 FY2017Sep 30, 2017$3.54M+4.7%
Q2 FY2017Jun 30, 2017$3.85M+35.8%
Q1 FY2017Mar 31, 2017$3.37M–
Q4 FY2016Dec 31, 2016$3.45M–
Q3 FY2016Sep 30, 2016$3.38M–
Q2 FY2016Jun 30, 2016$2.83M–

More Aldeyra Therapeutics figures

See a number that looks wrong?